A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis

Leukemia

Volumn 28, Issue 12, 2014, Pages 2304-2310

  Venner, C P ^a,b   Gillmore, J D ^a   Sachchithanantham, S ^a   Mahmood, S ^a   Lane, T ^a   Foard, D ^a   Rannigan, L ^a   Gibbs, S D J ^a,c   Pinney, J H ^a   Whelan, C J ^a   Lachmann, H J ^a   Hawkins, P N ^a   Wechalekar, A D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BORTEZOMIB PLUS CYCLOPHOSPHAMIDE PLUS DEXAMETHASONE; CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE PLUS DEXAMETHASONE PLUS THALIDOMIDE; DEXAMETHASONE; THALIDOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; IMMUNOGLOBULIN LIGHT CHAIN; PYRAZINE DERIVATIVE;

ADULT; AGED; AMYLOID LIGHT CHAIN AMYLOIDOSIS; AMYLOIDOSIS; ARTICLE; DEATH; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; COHORT ANALYSIS; COMPARATIVE STUDY; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84925286648     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.218     Document Type: Article

References (42)

1. Perfetti V, Vignarelli MC, Casarini S, Ascari E, Merlini G. Biological features of the clone involved in primary amyloidosis (AL). Leukemia 2001; 15: 195-202.
2. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121: 3420-3427.
3. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989-995.
4. Dispenzieri A, Gertz MA, Kumar SK, Lacy MQ, Kyle RA et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881-1887.
5. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202-1207.
6. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083-1093.
7. Palladini G, Perfetti P, Obici L, Caccialanza R, Semino A, Adami F et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936-2938.
8. Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007; 110: 787-788.
9. Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica 2013; 98: 789-792.
10. Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2013; 98: 433-436.
11. Tovar N, Cibeira MT, Rosiñol L, Solé M, de Larrea CF, Escoda L et al. Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease. Eur J Haematol 2012; 89: 340-344.
12. Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol 2012; 91: 89-92.
13. Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013; 27: 823-828.
14. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012; 119: 4860-4867.
15. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 2012; 119: 5384-5390.
16. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 2012; 119: 5397-5404.
17. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011; 118: 865-873.
18. Venner CP, Lane T, Foard D, Rannigan L, Gibbs SDJ, Pinney JH et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119: 4387-4390.
19. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119: 4391-4394.
20. Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457-464.
21. Gillmore J, Cocks K, Gibbs S, Sattianayagam PT, Lane T, Lachmann H et al. Cyclophosphamide, thalidomide and dexamethasone (ctd) versus melphalan plus dexamethasone (MD) for newly-diagnosed systemic al amyloidosis-results from the UK amyloidosis treatment trial. Blood (ASH Annu Meet Abstr) 2009; 114: Abstract 745.
22. Gibbs S, Gillmore JD, Sattianayagam PT, Lachmann HJ, Lane T, Goodman H et al. CTD versus Mel-Dex as upfront treatment in AL amyloidosis: a matched casecontrol study. Amyloid 2010; 17(Suppl 1): 83.
23. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949-2951.
24. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009; 113: 3040-3049.
25. Oliva L, Palladini G, Cerruti F, Pengo N, Cascio P, Merlini G et al. Assessing proteostasis and proteasome stress in light chain amyloidosis. Blood 2010; 116: 3992.
26. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031-1037.
27. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295-298.
28. Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC. Bortezomib and highdose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica 2011; 96: 1890-1892.
29. Gertz MA, Comenzo R, Falk RH, Fermand J-P, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328.
30. Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010; 17: 2.
31. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia 2012; 26: 2317-2325.
32. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541-4549.
33. Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013; 27: 941-946.
34. Wechalekar AD, Gillmore JD, Foard D, Rannigan L, Lane T, Pinney JH et al. Evaluation of an early switch to second line chemotherapy in AL amyloidosis among patients who fail to achieve a very good partial response to frontline treatment. XIII Symposia of the International Society of Amyloidosis, 2012, Groeningen, Netheralands, (OP 60).
35. Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D et al. Outcome in renal Al amyloidosis after chemotherapy. J ClinOncol 2011; 29: 674-681.
36. Lane T, Rannigan L, Foard D, Wechalekar A, Gibbs S. ALchemy-A large prospective 'Real World' Study of Chemotherapy in AL Amyloidosis. Blood 2011; 118: Abstract 992.
37. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011; 118: 4346-4352.
38. Cordes S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer 2012; 118: 6105-6109.
39. Warsame R, Bang S-M, Kumar SK, Lacy MQ, Buadi FK, Buadi F et al. Outcomes and treatments of relapsed al amyloidosis following stem cell transplant. Blood 2012; 120: 1858.
40. Pinney JH, Lachmann HJ, Sattianayagam PT, Gibbs SDJ, Wechalekar AD, Venner CP et al. Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance. Am J Transplant 2013; 13: 433-441.
41. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-2445.
42. Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem-cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013; 27: 823-828.